FOR IMMEDIATE RELEASE
[Boca Raton, FL, September 14, 2023] – Aventusoft, a pioneering research-driven company dedicated to developing innovative products that address heart conditions by challenging established paradigms, is thrilled to announce its selection to one of the National Institutes of Health (NIH) showcase companies to attend the annual HLTH Conference from October 8-11, 2023, in Las Vegas, NV.
The HLTH Conference, a paramount annual gathering that brings together the crème de la crème of the healthcare industry, will serve as the backdrop for the monumental launch of HEMOTAG Vitals by Aventusoft. Clinical studies have demonstrated its application in optimizing management of structural heart health, such as in patients with Heart Failure. This groundbreaking product exemplifies the company’s unwavering commitment to revolutionizing cardiac healthcare.
“We are both honored and excited for the opportunity presented to us by NIH. The HLTH Conference provides the perfect stage to introduce HEMOTAG Vitals to the world, showcasing our dedication to challenging and advancing cardiac care.”
Kaustubh Kale, Founder and CEO of Aventusoft.
We look forward to showcasing HEMOTAG Vitals, engaging with industry leaders, and gaining insights into the future of healthcare technology at the event.
For further details about Aventusoft, HEMOTAG Vitals, or its participation at the HLTH Conference,
please reach out to:
Kaustubh Kale, CEO
Aventusoft, headquartered in Boca Raton, FL, is at the forefront of cardiac healthcare innovation, with a dedicated focus on research-driven solutions that challenge and redefine conventional paradigms in heart care. With a robust commitment to excellence, Aventusoft consistently strives to break barriers in the realm of cardiac health, creating products that not only address but revolutionize the approach to heart conditions. Through a blend of groundbreaking research and cutting-edge technology originally developed for the US Department of Defense, Aventusoft stands as a beacon of hope for countless patients, offering them a brighter, healthier future.
About HEMOTAG ®
HEMOTAG® Vitals provides non-invasive hemodynamics designed specifically for detection and monitoring of the events of the cardiac cycle, providing validated markers of intracardiac pressure and congestion. HEMOTAG Vitals with its Centralized Care Coordination Platform enables one to see beyond the gold-standard invasive cardiac imaging, implantable devices, and blood draws, with a mission to make the impossible possible for use in monitoring structural heart health! By introducing our propriety non-invasive Quad sensing vibration technology-based biosensor and cloud platform for Rapid Heart Failure Vitals, that will revolutionize the way we can respond to structural heart health and Heart Failure in the coming decade. Providing absolute, accurate and actionable vitals for heart failure congestion from transthoracic acoustic cardiograph which previously were available only by surgical implants, or blood draws.
With its user-friendly mobile application, cloud dashboard for seamless centralized care coordination, and high-resolution imaging capabilities, HEMOTAG® Vitals streamlines monitoring, fostering timely interventions and enhancing patient care. Offering real-time results, enabling care providers to conduct immediate, accurate patient management.
The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important medical discoveries that improve health and save lives.